Explore more publications!
Health Wire Syria
Got News to Share?

Health Wire Syria: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Wire Syria.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 5, 2025

Gelteq Preclinical Study Demonstrates Enhanced Oral Delivery of Oil-Soluble and Poorly Soluble Drugs Using Its Gel-Based Platform
December 5, 2025

Gelteq Preclinical Study Demonstrates Enhanced Oral Delivery of Oil-Soluble and Poorly Soluble Drugs Using Its Gel-Based Platform

Indeterminate GlobeNewswire
Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis
December 5, 2025

Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis

Indeterminate GlobeNewswire
Curaechoice and Northwestern Memorial Healthcare Extend Partnership to Expand Access to No-Cost Healthcare for Curaechoice Members Nationwide
December 5, 2025

Curaechoice and Northwestern Memorial Healthcare Extend Partnership to Expand Access to No-Cost Healthcare for Curaechoice Members Nationwide

Indeterminate GlobeNewswire
Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting
December 5, 2025

Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting

Indeterminate GlobeNewswire
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
December 5, 2025

Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

Indeterminate GlobeNewswire
Accendatech US comments on the recent setback in phase 2 study to evaluate STAT3 as therapeutic target and other drug development strategies such as AI and precision medicine to treat patients with IPF
December 5, 2025

Accendatech US comments on the recent setback in phase 2 study to evaluate STAT3 as therapeutic target and other drug development strategies such as AI and precision medicine to treat patients with IPF

Indeterminate GlobeNewswire
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 5, 2025

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

Indeterminate GlobeNewswire
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
December 5, 2025

XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc

Indeterminate GlobeNewswire
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
December 5, 2025

Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures

Indeterminate GlobeNewswire
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
December 5, 2025

Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad

Indeterminate GlobeNewswire
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
December 5, 2025

New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer

Indeterminate GlobeNewswire
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum
December 5, 2025

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

Indeterminate GlobeNewswire
GeneLife Expands GeneAI Forecast With New Cancer Risk Prediction Models
December 5, 2025

GeneLife Expands GeneAI Forecast With New Cancer Risk Prediction Models

Indeterminate GlobeNewswire
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease
December 5, 2025

Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease

Indeterminate GlobeNewswire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 5, 2025

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
December 5, 2025

Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition

Indeterminate GlobeNewswire
Wugen to Present Correlative Data and Long-Term Follow-Up Updates for Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell therapy at the 2025 ASH Annual Meeting
December 5, 2025

Wugen to Present Correlative Data and Long-Term Follow-Up Updates for Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell therapy at the 2025 ASH Annual Meeting

Indeterminate GlobeNewswire
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform
December 5, 2025

Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform

Indeterminate GlobeNewswire
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 5, 2025

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
December 5, 2025

Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions